03:17 PM EDT, 05/02/2025 (MT Newswires) -- Novo Nordisk ( NVO ) said Friday the US Food and Drug Administration accepted its new drug application filing for an investigational 25 mg oral formulation of its obesity management drug Wegovy.

The FDA application for the oral Glucagon-like peptide-1 treatment is based on the results of a phase 3 trial, according to a statement.

The FDA will make a final decision on the application in Q4, the company said.

Wegovy injection 2.4 mg is currently approved for adults and children aged 12 years and older with obesity.

Shares were up 5.6% in recent trading.

Price: 69.18, Change: +3.58, Percent Change: +5.46